



| Agenda Item No: | 21 |
|-----------------|----|
|                 |    |

| Report to:  | Humber & North Yorkshire Integrated Care Board          |                  |
|---|---|------------------|
| Date of Meeting:  | 10 July 2024  |                  |
| Subject:  | Question to the Board                                   |                  |
| Director Sponsor:   | Karina Ellis, Executive Director of Corporate Affairs   |                  |
| Author:   | Mike Napier, Director of Governance and Board Se        | cretary          |
| STATUS OF THE REPORT:  Approve Discuss Assurance Information A Regulatory Requirement   |   |                  |
| SUMMARY OF REP  | ORT:  |                  |
| In accordance with ICB procedures, there is a standing item on the agenda of board meetings held in public where members of the public can submit up to two questions in advance relating to any item on the published agenda. It is at the discretion of the ICB Chair whether other questions not relating to an agenda item are taken at the meeting.  |   |                  |
| A public question ha  | s been received and approved for consideration by the C | hair as follows: |
| Autism is a neurological condition, not a medical condition. Is it part of the ICS/ICB remit to address the considerable deficit of both psychosocial support and social care for autistic adults, particularly those late identified, to prevent mental and physical health problems developing impacting suicide prevalence and reduced life expectancy; and if so, how does it propose to achieve and fund this? |   |                  |
| RECOMMENDATIO   | NS:   |                  |
| Members are asked   | to:   |                  |
| i) Receive the question and note that the response provided to the meeting will subsequently be sent in writing to the enquirer.  |   |                  |
| ICB STRATEGIC O   | BJECTIVE  |                  |
|   |   |                  |
| Leading for Excellen  | се  | $\boxtimes$      |
| Leading for Preventi  | on  | $\boxtimes$      |
| Leading for Sustaina  | bility  | $\boxtimes$      |
| Voice at the Heart  |   | $\boxtimes$      |

| IMPLICATIONS                                |   |  |
|---|---|--|
| Finance                                     | No adverse implications identified in relation to the submission of the question. |  |
| Quality                                     | No adverse implications identified in relation to the submission of the question. |  |
| HR  | No adverse implications identified in relation to the submission of the question. |  |
| Legal /<br>Regulatory                       | No adverse implications identified in relation to the submission of the question. |  |
| Data Protection /<br>IG                     | No adverse implications identified in relation to the submission of the question. |  |
| Health inequality / equality                | No adverse implications identified in relation to the submission of the question. |  |
| Conflict of Interest Aspects                | No adverse implications identified in relation to the submission of the question. |  |
| Sustainability                              | No adverse implications identified in relation to the submission of the question. |  |
| ASSESSED RISK: There are no risks           | identified in relation to this paper.   |  |
| MONITORING AN                               | D ASSURANCE: urance of the matter will be undertaken by the ICB Board.            |  |
| ENGAGEMENT: In line with the ICB required.  | procedure, the Board Secretary will facilitate subsequent follow-up, as           |  |
| REPORT EXEMPT FROM PUBLIC DISCLOSURE No Yes |   |  |